(Biphenyl-4-yl)methylammonium Chlorides: Potent Anticonvulsants That Modulate Na+ Currents
摘要:
We have reported that compounds containing a biaryl linked unit (Ar-X-Ar') modulated Na+ currents by promoting slow inactivation and fast inactivation processes and by inducing frequency (use)-dependent inhibition of Na+ currents. These electrophysiological properties have been drugs. In this study, we demonstrate that the readily accessible associated with the mode of action of several antiepileptic (biphenyl-4-yl)methylammonium chlorides (compound class B) exhibited a broad range of anticonvulsant activities in animal models, and in the maximal electroshock seizure test the activity of (3'-trifluoromethoxybiphenyl-4-yl)methylammonium chloride (8) exceeded that of phenobarbital and phenytoin upon oral administration to rats. Electrophysiological studies of 8 using mouse catecholamine A-differentiated cells and rat embryonic cortical neurons confirmed that 8 promoted slow and fast inactivation in both cell types but did not affect the frequency (use)-dependent block of Na+ currents.
(Biphenyl-4-yl)methylammonium Chlorides: Potent Anticonvulsants That Modulate Na+ Currents
摘要:
We have reported that compounds containing a biaryl linked unit (Ar-X-Ar') modulated Na+ currents by promoting slow inactivation and fast inactivation processes and by inducing frequency (use)-dependent inhibition of Na+ currents. These electrophysiological properties have been drugs. In this study, we demonstrate that the readily accessible associated with the mode of action of several antiepileptic (biphenyl-4-yl)methylammonium chlorides (compound class B) exhibited a broad range of anticonvulsant activities in animal models, and in the maximal electroshock seizure test the activity of (3'-trifluoromethoxybiphenyl-4-yl)methylammonium chloride (8) exceeded that of phenobarbital and phenytoin upon oral administration to rats. Electrophysiological studies of 8 using mouse catecholamine A-differentiated cells and rat embryonic cortical neurons confirmed that 8 promoted slow and fast inactivation in both cell types but did not affect the frequency (use)-dependent block of Na+ currents.
Compounds for the treatment of inflammatory disorders
申请人:Siddiqui Arshad M.
公开号:US20060178366A1
公开(公告)日:2006-08-10
This invention relates to compounds of the Formula (I):
or a pharmaceutically acceptable salt, solvate or isomer thereof, which can be useful for the treatment of diseases or conditions mediated by MMPs, aggrecanase, ADMP, LpxC, ADAMs, TACE, TNF-α or combinations thereof.
Compounds for the treatment of inflammatory disorders and microbial diseases
申请人:Siddiqui Arshad M.
公开号:US20070167426A1
公开(公告)日:2007-07-19
This invention relates to compounds of the Formula (I):
or a pharmaceutically acceptable salt, solvate or isomer thereof, which can be useful for the treatment of diseases or conditions mediated by MMPs, aggrecanase, ADMP, LpxC, ADAMs, TACE, TNF-α or combinations thereof.
COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS
申请人:Guo Zhuyan
公开号:US20100145048A1
公开(公告)日:2010-06-10
This invention relates to compounds of the Formula (I):
or a pharmaceutically acceptable salt, solvate or isomer thereof, which can be useful for the treatment of diseases or conditions mediated by MMPs, ADAMs, TACE, TNF-α or combinations thereof.